Price (delayed)
$17.89
Market cap
$265.75M
P/E Ratio
0.56
Dividend/share
N/A
EPS
$31.92
Enterprise value
$211.9M
neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed
There are no recent dividends present for NGNE.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.